

Supplementary Online Content

Qamar A, Giugliano RP, Keech AC, et al. Interindividual variation in low-density lipoprotein cholesterol level reduction with evolocumab: an analysis of FOURIER trial data. *JAMA Cardiol*. Published online December 12, 2018.
doi:10.1001/jamacardio.2018.4178

eTable. Interindividual Variability in Percent LDL-C Change at 4 Weeks Across Major Subgroups

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable. Interindividual Variability in Percent LDL-C Change at 4 Weeks Across Major Subgroups

Subgroup	Placebo	Evolocumab	Rank-Paired Placebo-Evolocumab	Percent of Patients with ≥50% LDL-C Reduction	Percent of Patients with ≥30% LDL-C Reduction
Age					
≥65 years (Placebo=4891; Evolocumab=4970)	-4 (+5, -13)	-68 (-57, -77)	-63 (-60, -64)	93	99.9
<65 years (Placebo=5975; Evolocumab=5932)	-4 (+7, -14)	-65 (-51, -75)	-60 (-56, -61)	88	99.6
Sex					
Female (Placebo=2625; Evolocumab=2665)	-4 (+7, -14)	-62 (-47, -72)	-56 (-52, -59)	80	99.9
Male (Placebo=8241; Evolocumab=8237))	-4 (+6, -13)	-68 (-56, -77)	-63 (-60, -64)	93	99.6
Race					
Non-Caucasian (Placebo=1627; Evolocumab=1596)	-6 (+5, -15)	-70 (-58, -79)	-63 (-61, -64)	97	99.6
Caucasian (Placebo=9239; Evolocumab=9306)	-3 (+6, -13)	-66 (-53, -76)	-61 (-59, -63)	89	99.8
Geographic Region					
North America (Placebo=1869; Evolocumab=1854)	-2 (+7, -12)	-63 (-51, -73)	-60 (-58, -61)	98	99.9
Europe (Placebo=6844; Evolocumab=6898)	-4 (+6, -13)	-66 (-53, -76)	-61 (-57, -63)	87	99.8
Latin America (Placebo=682; Evolocumab=696)	-6 (+4, -16)	-66 (-54, -76)	-59 (-58, -60)	95	99.4
Asia (Placebo=1471; Evolocumab=1454)	-5 (+5, -14)	-71 (-59, -80)	-65 (-63, -66)	98	99.7
High-Intensity Statin					
Yes (Placebo=7456; Evolocumab=7529)	-4 (+6, -14)	-65 (-52, -75)	-60 (-56, -62)	88	99.7
No (Placebo=3410; Evolocumab=3373)	-4 (+6, -13)	-69 (-57, -78)	-64 (-62, -65)	96	99.9
Baseline LDL-C ≥ 85 mg/dL					
Yes (Placebo=6696; Evolocumab=6662)	-5 (+4, -15)	-66 (-54, -75)	-60 (-56, -61)	87	99.7
No (Placebo=4170; Evolocumab=4240)	-2 (+9, -12)	-67 (-53, -78)	-64 (-61, -66)	94	99.9

Percent LDL-C change are expressed as median (interquartile change). Race was reported by the patients. Statin intensity was categorized in accordance with the guidelines of the American College of Cardiology and American Heart Association. LDL-C, low-density lipoprotein cholesterol.